Tech Company Financing Transactions
Aerovance Funding Round
Private investors participated in a $38 million Series C venture round for Aerovance. The round was announced on 4/8/2009.
Transaction Overview
Company Name
Announced On
4/8/2009
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
2929 7th St. 120
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Perry
Chief Medical Officer
Tunde Otulana
Chief Technical Officer
Robert Kuhn
Executive Vice President
David Happel
Browse more venture capital transactions:
Prev: 4/8/2009: Management Health Solutions venture capital transaction
Next: 4/8/2009: Ethertronics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs